Jerini
| Jerini AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| founding | 1994 |
| Seat | Berlin , Germany |
| management |
|
| Number of employees | 154 (December 31, 2008) |
| sales | € 7.9 million (2008) |
| Branch | drug |
The Jerini AG was a pharmaceutical company focused on peptide-based specialized medicines.
With the help of a technology platform “Peptides-to-Drugs” (P2D), research was carried out on active ingredients for drugs in the indication areas of ophthalmology, oncology and inflammatory diseases. In addition to developing its own active ingredients, the company cooperated with other companies.
In 2008, Jerini was taken over by the British company Shire plc .
Company history
Jerini started operations in 1994. In December 2008 the company had 154 employees.
Subsidiaries in the group were JPT Peptide Technologies GmbH and Jerini US, Inc.
Jerini was listed on the Prime Standard of the Frankfurt Stock Exchange and had acquired a total of over 130 million in financing from public and private funds.
The board consisted of:
- Jens Schneider-Mergener , CEO
- Adi Hoess, Head of Business Development
- Jochen Knolle, Head of Research & Development
- Berndt Modig, Chief Financial Officer
Takeover by Shire
Shortly after the drug Firazyr was approved for the rare hereditary disease hereditary angioedema, the company lacked the necessary capital to launch it, which is why it was sold to the British company Shire plc in the third quarter of 2008 .
Products
Icatibant (Firazyr®) is approved as a bradykinin receptor blocker for subcutaneous therapy for hereditary angioedema (HAE). The active ingredient was in-licensed from Aventis in 2001. On July 15, 2008, Jerini received Icatibant approval from the European Commission for the treatment of acute HAE attacks. This made Icatibant the first product to be approved for the HAE indication in all EU countries. It was initially launched in Germany and the UK.
On April 24, 2008, Icatibant received a Not Approvable Letter from the Food and Drug Administration (FDA) which threatened to delay the approval process in the USA. The Jerini share price then collapsed.
Jerini's technology platform
Jerini's proprietary technology platform Peptides-to-Drugs (P2D) enabled the identification of peptide precursor molecules and their systematic transformation into peptidomimetics (injectable) or low-molecular-weight drugs (orally administrable drugs). This enabled Jerini to develop novel drug candidates for diseases that were difficult to access using traditional drug research methods. The ability to produce both peptidomimetics and low-molecular-weight drugs as drug candidates made it possible to develop drugs for acute and chronic treatments against the same target at the same time.
Individual evidence
- ↑ a b c Jerini: Annual Report 2008 ( Memento from January 5, 2011 in the Internet Archive ). Retrieved May 7, 2014.
- ↑ transkript.de : Jerini sells to British Shire ( Memento of the original from November 6, 2013 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , July 3, 2008.
- ↑ finanznachrichten.de: Jerini AG and Shire Limited announce strategic partnership , July 3, 2008.
- ↑ Rote Liste ® Service GmbH (ed.): Red list -Arzneimittelverzeichnis for Germany . Rote Liste® Service GmbH, Frankfurt / M 2009 ( Rote-liste.de [accessed on April 17, 2009] DocCheck password required).
- ^ Finances.net: Jerini receives a Not Approvable Letter from the FDA , April 24, 2008.
- ↑ Federal Ministry of Education and Research: BioRegionen in Deutschland ( Memento of the original from September 23, 2015 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , 2006, accessed May 21, 2014
